Plasma Interleukin-6 Predicts Clinical Decline After Completion of Dexamethasone Therapy in Severe COVID-19

Plasma Interleukin-6 Predicts Clinical Decline After Completion of Dexamethasone Therapy in Severe COVID-19

OBJECTIVES:. To identify and characterize clinical decline after completion of dexamethasone in severe COVID-19 and determine whether interleukin (IL)-6 and other inflammatory biomarkers predict the occurrence of clinical decline. DESIGN:. Prospective observational cohort. SETTING:. ICUs in three Un...

Full description

Bibliographic Details
Main Authors: F. Linzee Mabrey, MD, Pavan K. Bhatraju, MD, MSc, Eric D. Morrell, MD, Leila R. Zelnick, PhD, Neha A. Sathe, MD, Nicholas G. O’Connor, BS, Carmen Mikacenic, MD, Thomas R. Martin, MD, W. Conrad Liles, MD, PhD, Mark M. Wurfel, MD, PhD
Format: Article
Language:English
Published: Wolters Kluwer 2022-12-01
Series:Critical Care Explorations
Online Access:http://journals.lww.com/10.1097/CCE.0000000000000813

Internet

http://journals.lww.com/10.1097/CCE.0000000000000813

Similar Items